Clinical Trials on Renal Impairment

Total 12577 results

Wockhardt
Clinartis

Completed

A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment

Renal Impairment

United States
Polyphor Ltd.

Completed

Pharmacokinetics and Safety of POL7080 in Patients With Renal Impairment

Renal Impairment

Germany
AbbVie

Completed

Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function

Renal Impairment

United States, New Zealand
FORUM Pharmaceuticals Inc
PRA Health Sciences

Completed

EVP-6124 Renal Impairment Study

Renal Impairment

Czech Republic, Hungary
ApoPharma

Completed

An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment

Renal Impairment

Canada
Bioprojet

Completed

Pharmacokinetics of BF2.649 in Renal Impairment

Renal Impairment

France
TME Pharma AG

Completed

A Phase I Clinical Trial to Evaluate the Effect of Renal Impairment on Pharmacokinetics of NOX-E36

Renal Impairment

Hungary, Moldova, Republic of
Pfizer

Completed

A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function

Renal Impairment

United States
Sanofi

Completed

Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal Impairment

Renal Impairment

Germany
Shionogi

Completed

A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants

Renal Impairment

United States
Insmed Incorporated

Completed

A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment

Renal Impairment

United States
Concert Pharmaceuticals

Completed

Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543

Renal Impairment

United States
Zogenix, Inc.

Completed

Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) in Subjects With Renal Impairment

Renal Impairment
Sunshine Lake Pharma Co., Ltd.

Completed

Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and ESRD

Renal Impairment

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Renal Impairment

Renal Impairment

China
Pfizer

Completed

A Renal Impairment Study for PF-04965842

Renal Impairment

United States, Belgium
AstraZeneca

Completed

Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment

Renal Impairment

United States
Pfizer

Terminated

A Renal Impairment Study for PF-06651600

Renal Impairment

United States
Pfizer

Completed

Lorlatinib Renal Impairment Study

Renal Impairment

United States
Novartis Pharmaceuticals

Completed

A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers

Renal Impairment

Germany, South Africa
Novartis Pharmaceuticals

Completed

Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment

Renal Impairment

Russian Federation
Novartis Pharmaceuticals

Completed

A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function

Renal Impairment

Germany, Bulgaria
Zealand Pharma

Completed

Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function

Renal Impairment

Hungary, Poland
Eisai Inc.
Purdue Pharma LP

Completed

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment

Renal Impairment

United States
Mallinckrodt

Terminated

Pharmacokinetic Assessment of Sodium Sulfide in Subjects With Impaired Renal Function

Renal Impairment

United States
Pfizer

Completed

Glasdegib Renal Impairment Study

Renal Impairment

United States
H. Lundbeck A/S

Completed

Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects

Renal Impairment

Germany
Trius Therapeutics LLC

Completed

A Pharmacokinetics and Safety Study in Subjects With Renal Impairment

Renal Impairment

United States
Dong-A ST Co., Ltd.

Completed

PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired Patients

Renal Impairment

Korea, Republic of
Sahlgrenska University Hospital, Sweden

Completed

Fluid Investigation Colloid vs Crystalloid Reg. Renal Hemodynamics and Function

Renal Impairment

Sweden
Sanofi

Completed

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment

Renal Impairment

United States
AstraZeneca

Completed

Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function

Renal Impairment

United States
Repros Therapeutics Inc.

Terminated

Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females

Renal Impairment

United States
Galapagos NV

Completed

Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects

Renal Impairment

Germany
Sanofi

Completed

Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment

Renal Impairment

United States
Genzyme, a Sanofi Company

Completed

Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment

Renal Impairment

United States
Vanda Pharmaceuticals

Completed

Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function

Renal Impairment

United States
Merck KGaA, Darmstadt, Germany

Completed

Pharmacokinetics in Subjects With Renal Impairment

Renal Impairment

Germany
LEO Pharma

Completed

The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847

Renal Impairment

Canada
Astellas Pharma Inc

Completed

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

Renal Impairment

United States
Newron Pharmaceuticals SPA

Completed

Safinamide Renal Impairment Trial

Renal Impairment

Germany
Pfizer

Completed

Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function

Renal Impairment

United States
Cephalon

Completed

A Study to Assess the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Renal Function and Subjects With Varying Degrees of Renal Impairment

Renal Impairment

United States
Anthera Pharmaceuticals

Terminated

A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function

Renal Impairment

United States
Chipscreen Biosciences, Ltd.

Recruiting

Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function

Renal Impairment

China
Taiho Oncology, Inc.

Completed

Evaluating Patients With Varying Degrees of Renal Function

Renal Impairment

United States
AstraZeneca
Parexel

Completed

A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers

Renal Impairment

Bulgaria
Janssen Pharmaceutica N.V., Belgium

Terminated

A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult Participants

Renal Impairment

Germany
Novartis Pharmaceuticals

Completed

Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment.

Renal Impairment

Czechia, Germany, Romania, Bulgaria
Spero Therapeutics

Completed

Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function

Renal Impairment

United States

3

Subscribe